CTIS2023-506282-66-00招募中1 期
ECLECTIC: EstroTEP and circulating biomarkers to determine the optimal second line therapy for ER-positive HER2-negative metastatic breast cancer patients - IC 2022-12
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
入选标准
- •Metastatic invasive breast carcinoma of no special type, Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and any protocol-related procedures including screening evaluations., Signed informed consent., Patient affiliated to a social security system., Females of age =18 years., Life expectancy > 3 months., Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2., Estrogen Receptor (ER)-positive (=10%) and HER2-negative (ASCO/CAP guidelines) breast cancer, per local assessment on the most recent breast cancer tissue examined., Tumor block FFPE (primary tumor or metastasis) available., Patients whose disease has progressed on first line endocrine therapy with aromatase inhibitor and CDK4/6 inhibitor and who are deemed eligible, per investigator assessment, to a second line endocrine therapy. The progression on first line endocrine therapy with aromatase inhibitor and CDK4/6 inhibitor must have occurred after more than 6 months on treatment., Patients with available 18F-FDG PET/CT imaging, Evaluable disease per RECIST criteria and measurable disease per PERCIST criteria.
排除标准
- •Other breast cancer subtype (e.g. invasive lobular breast carcinoma)., History of previous cancer or hematological malignancy within 3 years preceding patient enrollment in the trial. Multiple primary breast cancers (controlateral/ipsilateral cancers/local relapses) are allowed pending all tumors were ER+ HER2-., Persons deprived of their freedom or under guardianship or incapable of giving consent., One or more prior line of chemotherapy in the metastatic setting., Any other antineoplastic therapy given at metastatic disease than the first line therapy with aromatase inhibitor and CDK4/6 inhibitor., Visceral crisis, per investigator’s assessment., Liver-only metastases., Prior exposure to any authorized or experimental agent degrading the estrogen receptor (fulvestrant, oral SERDs, PROTAC, etc)., Pregnancy or lactation period., In women of childbearing potential or premenopausal women or women with amenorrhea of less than 12 months, without adequate non-hormonal contraceptive measures (barrier methods, intrauterine contraceptive devices, sterilization; LHRH agonist cannot be considered as an efficient contraceptive measure), positive urinary or serum pregnancy test 72 hours before 18F-FES PET/CT., Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease. Patients with a history of CNS metastases or cord compression are eligible if they have been treated with local therapy (e.g., radiotherapy, stereotactic surgery) and are clinically stable and off anticonvulsants and steroids for at least 4 weeks before treatment start.
研究者
相似试验
招募中
3 期
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer PatientsBreast CarcinomaNCT06195709Institut Curie300
尚未招募
2 期
A study to check the outcomes of Triple Negative Breast Cancer patients with the presence of Estrogen receptor Beta and TP53 mutation and the outcomes of adding the drug Tamoxifen in these patients.CTRI/2023/09/057359AVNEET KAILASH AGRAWA
招募中
不适用
Circulating biomarkers in hormone-producing tumorsJPRN-jRCT1040200050Takamura Toshinari420
招募中
2 期
Biomarkers to Detect Endocrine Therapy ResistanceMetastatic CancerLobular Breast CarcinomaBreast CancerNCT06067503University of Wisconsin, Madison8
进行中（未招募）
1 期
CROSS-OVER COMPARISON OF TESTOSTERONE SERUM LEVELS IN HYPOGONADAL MEN TREATED WITH L0074 TESTOSTERONE PATCH 60CM2 (2 patches/48H) AND ORAL TESTOSTERONE UNDECANOATE -PANTESTONE® 40mg- (2 caps, bid) - NAEUCTR2004-004891-36-ESPIERRE FABRE MEDICAMENT55